I’m an independent inventor who recently filed a provisional patent through the USPTO’s own online system. The system malfunctioned during submission, and USPTO support staff gave me specific instructions on how to work around the bugs and when to pay the fee. They later confirmed in writing that the payment had been posted.

Despite that, the Office issued a surcharge claiming the payment was late and threatened abandonment if I didn’t pay within two months. I paid the surcharge under protest and filed a formal Petition to the Director of the USPTO, asking for a refund because the delay was caused by their own system errors and instructions. That petition was sent to the Director and several other USPTO offices.

Since then, they have been deliberately evading addressing the issue for several months. Their responses have ranged from utter inaction to vague, generic replies that carefully avoid the core problem. This is not a small clerical glitch; it shows an agency that isn’t stepping up even when confronted with its own mistakes. My concern is this could plant seeds for retaliation during actual examination.

Usually, the USPTO has various initiatives to assist pro‑se filers, but in this case it feels like the system is actively working against them. I looked into the USPTO‑affiliated law‑school clinic route, but almost all of them discriminate against out‑of‑state inventors, despite it being a federal program, and those that don’t claim limited resources or overflowing caseloads.

In Florida, where I live, there are some 11 ABA‑accredited law schools, yet almost none of them participate in a USPTO clinic, which is itself a little odd when even small, non‑ABA‑accredited schools in other states, with just one faculty member for the entire school, manage to run a national patent‑clinic program.

But even that route is risky because exposing a patent with high commercial value to so many eyes has its own risks.

That’s why I need a real patent attorney to handle the next steps:

converting this provisional into a nonprovisional in the US,

and expanding protection into key markets like the UK, Canada, and Australia.

Relying on the same USPTO‑run process that broke, then charged me a surcharge, and then ignored a formal petition to the Director is not a safe way to protect this idea.

None of this is an investment. There’s no equity, no profit‑share, no guarantee of a product. Your support is the difference between this idea being buried in USPTO‑run paperwork jungle, or getting a real shot at protection and development.